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Plasma concentration monitoring of aminoglycosides
F. Follath, M. Wenk and S. Vozeh
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Basle, Switzerland
A narrow therapeutic margin and poor predictability of plasma concentrations
are the main reasons for drug level monitoring during aminoglycoside treatment.
Gentamicin, tobramycin, amikacin and netilmicin can now be accurately and
rapidly measured by radioenzymic, radio-immuno and enzyme-immuno assays.
Routine determinations of peak (1-2 h post dose) and trough levels are recom-
mended to ensure adequate dosage in all patients with serious Gram-negative
infections, especially when renal function is impaired. It should be realized,
however, that maintaining aminoglycoside concentrations within a given range
will only reduce, but not entirely eliminate the risk of toxicity. The pharmaco-
kinetic behaviour of these antibiotics leads to a progressive drug accumulation in
renal tissue and the inner ear, which depends both on dosage amd duration of
treatment.
Une marge therapeutique etroite ainsi que la difficulte a predire les concentration
plasmatiques, sont les principales raisons de controle des taux sanguins au cours
d'un traitement par les aminoglycosides. Aujourd'hui les concentrations de
gentamicine, tobramycine, amikacine et netilmicine peuvent etre mesurees
rapidement et de maniere precise par les methodes radio-enzymatiques, radio-
immunologiques et enzymo-immunologiques. La determination du pic (1 a 2
heures apres administration) et du taux residuel est recommandee pour assurer un
dosage adequat chez tous les malades atteints d'une infection severe a germes
Gram-negatif, et particulierement en cas d'insufTisance renale. II faut pourtant
bien garder a l'esprit, que le fait de maintenir la concentration d'une amino-
glycoside a un niveau donne, permet seulement de diminuer les risques de
toxicite, mais pas de les eliminer totalement. La pharmacocinetique particuliere
de ces antibiotiques entraine une accumulation progressive dans le parenchyme
renal et dans l'oreille interne, qui depend a la fois de la posologie et de la duree du
traitement.
Monitoring of serum drug levels is often recommended to guide the dosage of
aminoglycosides, especially in patients with reduced renal function. Despite the
widespread use of these antibiotics, such measurements are only practised in a few
specialized laboratories. However, recent progress has resulted in more rapid, simple
and specific assays that would potentially allow routine determination of
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gentamicin, tobramycin, amikacin and netilmicin in most hospitals. Before
advocating this policy, a critical reassessment of the practical value of amino-
glycoside monitoring is necessary to justify the demands for additional manpower
and equipment. Does the knowledge of plasma concentrations really increase the
effectiveness and safety of aminoglycoside treatment?
Rationale of drug level monitoring
For any drug, plasma concentration measurements are meaningful only if the
following basic requirements are fulfilled:
(1) the difference between therapeutic and toxic doses is small (narrow
therapeutic margin);
(2) plasma concentrations on standardized dosage are highly variable;
(3) a direct relationship can be shown to exist between drug levels and
therapeutic or toxic effects.
Some of these reasons are relevant to the measuring of aminoglycoside serum levels.
In spite of careful adaptation of antibiotic dosage, damage to the kidney or eighth
nerve cannot be entirely avoided with any of the available agents. An advantage of
tobramycin over gentamicin with respect to nephrotoxicity (Smith et ai, 1980), and
of netilmicin over amikacin for ototoxicity (Barza et ai, 1980) has been reported, but
a 12-15% incidence of side-effects still occurred even with the 'better tolerated'
drugs. Although the risk of aminoglycoside treatment is probably much lower in
patients with less severe infections, the narrow margin of safety remains a cause for
continuing concern.
A further well-known problem of aminoglycoside treatment is the poor
predictability of serum levels (Barza & Lauermann, 1978). Wide variations can be
observed, especially, when prescribing is based only on the clinical judgement of
physicians (Mawer et ai, 1974). Various dosing aids have therefore been developed
that include age, sex, body weight, serum creatinine or creatinine clearance, to
estimate optimum dose requirements. Special computer-derived guidelines were
shown to achieve a statistically significant correlation between predicted and
measured concentrations of gentamicin (Hull & Sarubbi, 1976) or amikacin (Sarubbi
& Hull, 1978) obtained in patients. However, in individual cases even with these
nomograms up to 100% differences may occur between the target and plasma levels
actually achieved.
The third reason for monitoring, that is the demonstration of adequate serum
concentrations, is more controversial than generally assumed. Optimum ranges of
peak concentrations of 5-10 mg/1 are usually cited for gentamicin or tobramycin and
20-30 mg/1 for amikacin, but hard data to substantiate these values are difficult to
find. It appears logical that peak serum concentrations should be higher than the
minimum inhibitory concentration of the micro-organism causing the infection.
However, it is not known how much higher and during what fraction of the dosing
interval the bactericidal levels should be maintained.
No uniform views exist about toxic serum concentrations. As shown in Table I,
different authors have reached quite dissimilar conclusions in trying to decide
whether peak or trough are more relevant. All possible combinations of negative or
positive answers have been found. The discrepancies with regard to tolerable Cma,
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Table I. Relation between plasma levels and toxicity of aminoglycosides
. . . ^ Nephrotoxicity Ototoxicity
Author Drug
 r r r r '
^max ^min '-max *-min
Dahlgren, Anderson & Hewitt (1975) Gentamicin no yes - -
Blackef al. (1976)
Smithe,a/.(,978)
Schentage/a/. (1978)
Gailiunas etal. (1978)
Bock, Edelstein& Meyer (1980)
values may be explained by differences in the mode of drug administration and the
timing of blood samples, since during the early distribution phase great concentra-
tion changes occur within a short time. To study the influence of peak levels on
toxicity a standardization of blood sampling would be necessary. Such obvious
reasons cannot be the only explanation of the contradictory findings about the role
of trough levels.
Are there other factors, such as total dose and duration of treatment, that also
influence aminoglycoside toxicity? The data of Mawer et al. (1974), Black et al.
(1976), Gailiunas et al. (1978) and Bock, Edelstein & Meyer (1980) indicate an
increased risk of ototoxicity with prolonged treatment and higher cumulative dosage.
Current knowledge of the pharmacokinetic behaviour of this antibiotic group
supports the assumption that drug accumulation in the organ is an important cause
of toxicity. Contrary to earlier views on the elimination of aminoglycosides, a slow
terminal excretion phase is present not only after gentamicin or tobramycin but also
with netilmicin (Wenk et al, 1979), sissomicin (Follath et al., 1978) and amikacin
(Wenk & Follath, 1980). As a consequence, on repetitive dosing drug concentrations
will increase progressively in certain tissues, even though serum levels are
maintained within a recommended range. Prediction of drug levels in the body from
a multicompartment kinetic model was remarkably accurate in the patients of
Schentag et al, (1977). We therefore propose to consider not only peak or trough
serum concentration, but also the area under the serum concentration curve during a
dosing interval as a parameter relevant to toxicity. By computer simulations it can
be shown that the area under the curve correlates directly with drug amounts in the
peripheral tissue compartment (Figure 1). A dosing regimen producing a greater area
is therefore more likely to result in stronger aminoglycoside accumulation. The
values of the area under the cuvre can be easily approximated graphically if two
serum concentrations during a dosing interval are available (Figure 2). Further
studies will be required to evaluate the clinical usefulness of this criterion.
Methods for measuring aminoglycoside levels
If it is accepted that serum concentration measurements are clinically helpful, we
have to use appropriate methods to obtain reliable results rapidly. Among the
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Figure 1. Computer simulation of 2 dosing regimens for tobramycin resulting in identical trough serum
concentrations, but significantly different accumulation in the deep tissue compartment. Pharmacokinetic
parameters reported by Schentag et al (1978), were used assuming a creatinine clearance of 15 ml/min.
20mg8 hourly, 72 mgevery 24 h.
8 /(h)
AUC' InC, - lnC2
Figure 2. Estimation of the area under the serum concentration curve (AUC) during a dosing interval
from 2 serum concentration measurements. C, = concentration I h after the dose, C2 = concentration
immediately before the next dose, k = elimination rate constant, t = time of blood sample.
available techniques the following four types appear suitable for routine monitoring
of aminoglycoside treatment: (A) microbiological assays, (B) radioenzymatic assays
(REA), (C) radioimmunoassays (RIA), and (D) enzyme immunoassays.
Each of these methods has its advantages and problems, which should be carefully
considered in the selection of the most convenient solution for a particular
laboratory.
The agar-diffusion method has a reasonable degree of accuracy, is easy to perform
and is inexpensive. However, microbiological measurements are influenced by the
presence of other antibiotics, require about 5-18 h to give the results, and their
reproducibility is not as good as that of the newer techniques.
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Radioenzymatic assays are highly specific, sensitive and less time consuming than
the bioassays (Holmes & Sanford, 1974; Smith et ai, 1974). A strictly linear standard
curve allows accurate measurements over a wide range of concentrations. We found
these assays very reliable for the determination of serum and urinary levels of
gentamicin, tobramycin, amikacin, netilmicin and sissomicin. The main problem is
the production of qualitatively acceptable adenylating and acetylating enzymes.
Special equipment and trained personnel are essential.
Radioimmunoassays are most sensitive and highly specific. Various kits are now
commercially available for gentamicin, tobramycin, netilmicin and amikacin. A
disadvantage of this method is a need for a well-equipped laboratory and the costs of
test material. On the whole, radioenzymic and radioimmunoassays are equally
suitable for clinical use, and their comparisons show excellent correlations (Watson
& Wenk, 1978; Minishew, Holmes & Baxter, 1975). More recently, the enzyme
multiplied immunoassay technique (EMIT) has also been developed for gentamicin
and tobramycin. Instead of radioactive markers an enzyme-antigen complex,
specific antibody and an enzyme-substrate are added to the test serum; aminoglyco-
side concentrations are indicated by a change in light-absorbance that can be
measured by a spectrophotometer. Studies in our laboratory (Wenk et ai, 1980)
and by others (Phaneuf, Francke & New, 1980; Oeltgen, Hamann & Blouin, 1981;
Francke et ai, 1981) revealed a good correlation between results obtained by
radioenzymatic or radioimmunoassays and this new technique. By a simple
modification we could also use the gentamicin EMIT kit for measuring netilmicin
concentrations. The main interest of enzyme-immunoassay is its rapidity and
simplicity. An adaptation to semi-automated or automated enzyme analyzers seems
to be possible, and so specially trained personnel is not required. However, the costs
of EMIT reagents are high, a factor that could limit widespread use.
When should aminoglycoside levels be monitored?
In view of the practical problems with aminoglycoside dosage and the availability
of reliable assay techniques, monitoring of serum concentrations can be recom-
mended to improve effectivity and reduce toxicity. Measurements are indicated in
the following situations:
(1) Severe Gram-negative infections in patients with normal renal function in
order to ensure bactericidal antibiotic levels. Post-distribution levels (peak)
should be determined 1 or 2 h after intravenous or intramuscular admini-
stration, respectively. Additional blood samples are needed only in cases of
prolonged aminoglycoside treatment or if a tendency to rising creatinine
values is seen.
No monitoring is required in patients treated for uncomplicated urinary
infection, in whom the dosage interval can often be extended to 24 h or even
longer.
(2) In patients with slight to moderate renal impairment, both peak and trough
levels should be obtained to control the adequacy of the dosing regimen.
Trough levels repeated every 5-7 days will allow early recognition of
abnormal drug accumulation.
(3) In advanced renal failure (Clcr < 15 ml/min) repeated serum level measure-
ments are always indicated to avoid toxic concentrations, but at the same
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time to maintain therapeutically effective peak values. Especially in cases
with rapidly changing clinical condition, as often seen in septicaemia, close
monitoring with repeated blood sampling is necessary.
(4) Aminoglycoside treatment in neonates and small children should probably
also be included in this list.
In conclusion, the monitoring of serum levels makes the clinical use of aminoglyco-
sides easier, but this possibility should not lead to a more generous prescription of
these antibiotics. Even close surveillance and adaptation of dosage will not eliminate
the risk of toxicity. Not only the daily dose, but also the duration of treatment should
be limited.
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